ENLOE COURTNEY C 4

What Happened

• Courtney C. Enloe, EVP, General Counsel & Secretary of Bio‑Rad Laboratories (BIO), had 186 restricted stock units (RSUs) vest on April 24, 2026. The RSUs converted to 186 shares of Class A common stock.
• To satisfy tax withholding, 77 of those shares were withheld at a per‑share value of $287.84 for a total withholding of $22,164. Net shares delivered to Enloe were approximately 109 shares.
• The filing reports the RSU conversion (derivative exercise/conversion) and the withholding (tax payment) — this is receipt of an award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-04-24.
• Vesting/conversion: 186 RSUs -> 186 shares (reported as derivative exercise/conversion).
• Tax withholding: 77 shares disposed @ $287.84 = $22,164 (reported as payment of tax liability).
• Net shares retained by insider: ~109 shares (186 − 77).
• Footnotes of note:
  • F1/F3: Shares were acquired on RSU vesting; each RSU equals one share.
  • F4: These RSUs are part of a 744‑unit grant on April 24, 2024, vesting in four equal annual installments (186 shares per installment).
  • F2: Notes inclusion of small ESPP purchases from 2025 (6.1520 and 5.6340 shares) in related ownership disclosures.
• Shares owned after the transaction are not provided in the excerpt shared here.

Context

• This was a routine vesting of RSUs, not an open‑market buy or directional sale; the only disposition reported was share withholding to cover taxes (a common cashless mechanism).
• For retail investors, RSU vesting indicates compensation being converted to stock for the executive; withholding does not signal a sale for liquidity beyond tax obligations.